The board meeting for Theravance Biopharma Inc is scheduled for today, for the purpose of H.C. Wainwright 3rd Annual BioConnect Investor ConferenceSee details
Theravance Biopharma Inc has a share price target of US$ 15, revenue growth forecast of 40.0%, and profit growth estimate of 60.2% for FY25, based on top 4 analyst calls.